Default company panoramic image

Alma Bio Therapeutics

Alma’s pioneering disease-modifying therapy reinstates balance in a dysregulated immune system that lets inflammation run wild.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Lyon, RA, France
  • Currency CHF
  • Founded November 2013
  • Employees 4

Company Summary

Alma brings forward the first ever curative approach for autoimmune and auto inflammatory diseases of complex etiology . Alma’s therapeutic strategy utilizes body molecules that function as natural Physiological Regulators for managing inflammation. This game-changing approach constitutes a significant extension of immune-modulation therapy to an entirely novel field, achieving groundbreaking therapeutic results that are both effective and safe.


  • Default avatar
    Dr. Binah Baum
    Founder and CEO

    Dr. Baum is highly skilled in the university industry interface, in the commercialization of biomedical technologies and in the creation and nurturing of early-stage companies and incubator start-ups. She began her professional career at the VC firm of Adler & Co. She served as VP in 2 israeli VCs, as VP BD at Israel's leading incubator, as consultant to incubators, TTOs and bioclusters and for 5 years on the steering committee of CEBR.

  • Default avatar
    Prof. Irun R. Cohen MD
    Founder, Inventor and CSO

    Prof. Cohen has been the Mauerberger Professor of Immunology at the Weizmann Institute of Science; Director, European Collaboration on T Cell Vaccination. Director, Robert Koch-Minerva Center for Research in Autoimmune Diseases; Director of NIBN -the National Institute of Biotechnology in the Negev. Awarded the Robert Koch Prize in autoimmunity ,the Teva Founders Prize, the AESKU Prize and a European Federation of Immunological Societies Prize.

  • Default avatar
    Raanan Margalit
    Founder and CTO

    Highly experienced in the development and the utilization of animal models in early­stage drug discovery, with special emphasis on autoimmune and inflammatory diseases,cancer,neurodegenerative disorders as well as disease models involving surgical procedures and/or transplantation. Highly experienced in devising unconventional solutions as well as in guiding company management through the early stages of preclinical work through PoP.

  • Default avatar
    Dr. Victor de Souza
    Regulatory Consultant

    Senior advisor providing expertise and consultancy services to the pharmaceutical industry in regulatory affairs, research and development, and quality affairs/ compliance for new chemical or biotech product development, for marketed products and for generic products. Previously headed regulatory affairs at Speedel, Pharma Division, UCB S.A., F. Hoffmann-La Roche Ltd., Basel and Research Co-Director, Clin Pharm - OSU Cancer Center Ohio.


  • Default avatar
    FIDAL, Lyon
    Default avatar
    Orial, Lyon

Previous Investors

  • Default avatar
    Self - founders
    Default avatar
    Weizmann Institute of Science